Medtronic Enters New Outcomes-Based Insulin Pump Deal With Aetna

The device-maker will be on the hook to provide rebates to the health insurer if its self-adjusting insulin pumps don't maintain patients in appropriate glucose ranges, under a newly inked agreement. Medtronic already has a similar arrangement with UnitedHealthcare.

In a show of the growing emphasis on value-based care, Medtronic PLC has entered into an agreement for its products to be reimbursed by Aetna Inc. based on how well patients do on their self-adjusting insulin pump systems. The device-maker says patients on their pumps manage their disease better, which reduces cost to the insurer. Ultimately, Medtronic wants to expand incentives for patients currently treated with daily insulin injections to adopt the pump systems.

"The agreement will measure health outcomes for those patients that choose to transition to pump therapy using a Medtronic insulin...

More from Policy & Regulation

More from Medtech Insight

With CMS Coverage Established, Medtronic Looks To Next Steps For Renal Denervation

 
• By 

US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the

House Bill Calls For ‘Non-Flushable’ Label On Personal Wipes

 

The US House of Representatives passes legislation requiring manufacturers of non-flushable wet wipes to label products as ‘non-flushable," a move endorsed by the Personal Care Products Council.

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.